Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA).

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Client Outlook, a provider of FDA Class II diagnostic and clinical image viewing solutions, announced recently that Chinese company eimageglobal has selected eUnity as its diagnostic enterprise image viewing platform, and both parties have formed a strategic long-term partnership. Eimageglobal’s physician/patient/scheduling platform won the China National Innovation and Entrepreneurial award this year, and the integration of eUnity allows physicians, healthcare providers and patients to have increased and timely access to critical health information.